Clarke A E, Petri M, Manzi S, Isenberg D A, Gordon C, Senécal J-L, Penrod J, Joseph L, St Pierre Y, Fortin P R, Sutcliffe N, Richard Goulet J, Choquette D, Grodzicky T, Esdaile J M
Division of Clinical Epidemiology, Department of Medicine McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
Rheumatology (Oxford). 2004 Aug;43(8):1016-24. doi: 10.1093/rheumatology/keh229. Epub 2004 Jun 1.
Health consumption and health status in SLE in three countries with different health funding structures were compared.
Seven hundred and fifteen SLE patients (Canada 231, USA 269, UK 215) were surveyed semi-annually over 4 yr for health resource utilization and health status. Cross-country comparisons of (i) cumulative health expenditure (calculated by applying 2002 Canadian prices to resources in all countries) and (ii) disease damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, SLICC/ACR DI) at study conclusion were performed after adjustment. Missing expenditure and damage data were managed through multiple imputation using best predictive regressions with all available data from all patients as potential covariates.
Four hundred and eighty-five patients provided data at study entry and conclusion and at least four resource questionnaires (Canada 162, USA 157, UK 166); 41 died (Canada 13, USA 18, UK 10); 189 withdrew, were lost to follow-up or provided data at entry and conclusion but fewer than four resource questionnaires (Canada 56, USA 94, UK 39). At conclusion, after imputation, in Canada, the USA and the UK respectively, mean cumulative costs per patient over 4 yr [95% confidence interval (CI)] were $15,845 (13,509, 18,182), $20,244 (17,764, 22,724) and $17,647 (15,557, 19,737) and mean changes in SLICC/ACR DI were 0.49 (0.39, 0.60), 0.63 (0.52, 0.74) and 0.48 (0.39, 0.57). After adjustment for baseline differences, on average (95% CI), Canadian and British patients utilized 20% (8%, 32%) and 13% (1%, 24%) less resources than patients in the USA respectively, but experienced similar health outcomes.
Despite patients in the USA incurring higher health expenditures, they did not experience superior health outcomes.
比较三个具有不同卫生资金结构国家中系统性红斑狼疮(SLE)患者的健康消费和健康状况。
对715例SLE患者(加拿大231例、美国269例、英国215例)进行为期4年的半年度调查,以了解其卫生资源利用情况和健康状况。在调整后,对研究结束时(i)累计卫生支出(通过将2002年加拿大价格应用于所有国家的资源来计算)和(ii)疾病损害(系统性红斑狼疮国际协作诊所/美国风湿病学会损害指数,SLICC/ACR DI)进行跨国比较。缺失的支出和损害数据通过多重填补法处理,使用最佳预测回归,将所有患者的所有可用数据作为潜在协变量。
485例患者在研究开始和结束时提供了数据,并至少提供了四份资源问卷(加拿大162例、美国157例、英国166例);41例死亡(加拿大13例、美国18例、英国10例);189例退出、失访或仅在开始和结束时提供了数据,但资源问卷少于四份(加拿大56例、美国94例、英国39例)。在填补后,研究结束时,加拿大、美国和英国每位患者4年的平均累计成本[95%置信区间(CI)]分别为15,845美元(13,509,18,182)、20,244美元(17,764,22,724)和17,647美元(15,557,19,737),SLICC/ACR DI的平均变化分别为0.49(0.39,0.60)、0.63(0.52,0.74)和0.48(0.39,0.57)。在对基线差异进行调整后,平均而言(95%CI),加拿大和英国患者分别比美国患者少使用20%(8%,32%)和13%(1%,24%)的资源,但健康结果相似。
尽管美国患者的卫生支出较高,但其健康结果并不更好。